Although many studies have demonstrated that ATMs profoundly reprogram their functions in obesity-related cancers, ATM-targeted treatments according to different activation mechanisms have not been thoroughly investigated. This evidence concerns the gene ATM and obesity due to melanocortin 4 receptor deficiency.